Signum Biosciences business strategy and R&D program are well aligned to discover, develop and commercialize proprietary Signal Transduction Modulators (STM). These compounds compensate for signaling imbalances that diminish health and cause disease. We are focused on therapeutics that are well protected by intellectual property and are developing them for indications that can be commercialized in the near term. We are spinning off FDA-exempt skincare and nutraceutical products to build early revenue while we proceed towards FDA-approved drugs. We expect to out-license our products to both skin care and pharmaceutical companies. We maintain a modest burn rate by taking advantage of academic and corporate collaborations to effect basic research, by carefully organizing testing and preclinical development, and by targeting indications with inexpensive development paths.
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.